A new approach to comparing anti-CD20 antibodies: Importance of the lipid rafts in their lytic efficiency

OncoTargets and Therapy

Volumn 3, Issue , 2010, Pages 99-109

  Hammadi, Mariam ^a   Pers, Jacques Olivier ^a   Berthou, Christian ^a   Youinou, Pierre ^a   Bordron, Anne ^a  

^a Universite de Brest   (France)

Author keywords

Anti CD20 antibodies; B cell disorders; Lipid rafts; Lymphocyte B

Indexed keywords

B CELL ACTIVATING FACTOR; BLX 301; CASPASE 3; CD20 ANTIBODY; CD59 ANTIGEN; CHOLESTEROL; DECAY ACCELERATING FACTOR; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOSIDE GM3; IBRITUMOMAB TIUXETAN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1.5.3; MONOCLONAL ANTIBODY CD20; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PHOSPHATIDYLSERINE; PROTEIN BCL 2; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE LYN; RITUXIMAB; SPHINGOMYELIN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VELTUZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANCA ASSOCIATED VASCULITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DERMATOMYOSITIS; DRUG EFFICACY; DRUG MECHANISM; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; KIDNEY GRAFT REJECTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LIPID ANALYSIS; LIPID RAFT; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOMA; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; POLYMYOSITIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 78651376117     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Vollmers HP, Brändlein S. Natural antibodies and cancer. N Biotechnol. 2009;25(5):294-298
2. Chan OT, Madaio MP, Shlomchik MJ. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol. 1999;163(7):3592-3596
3. Xu H, He X, Sun J, Shi D, Zhu Y, Zhang X. The expression of B-cell activating factor belonging to tumor necrosis factor super family (BAFF) significantly correlated with C4D in kidney allograft rejection. Transplant Proc. 2009;41(1):112-116
4. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-762
5. Martin B, Craig P, Grattan C, et al. Low-grade B-cell proliferation progressing to high-grade B-cell lymphoma. Am J Dermatopathol. 2009; 31(6):578-581
6. Defoiche J, Debacq C, Asquith B, et al. Reduction of B cell turnover in chronic lymphocytic leukemia. Br J Haematol. 2008;143(2): 240-247
7. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6): 2188-2195
8. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217-2224
9. Pers JO, Devauchelle V, Daridon C, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximabtreated patients with Sjögren's syndrome. Arthritis Rheum. 2007;56(5): 1464-1477
10. Garrett HE Jr, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann Thorac Surg. 2002;74(4):1240-1242
11. Cheson B. Bexxar (Corixa/GlaxoSmithKline). Curr Opin Investig Drugs. 2002;3(1):165-170
12. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(9): 2652-2661
13. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009;27(20):3346-3353
14. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-5495
15. Stolz C, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma. 2009;50(6):873-885
16. Pawluczkowycz AW, Beurskens FJ, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749-758
17. Weitzman J, Betancur M, Boissel L, Rabinowitz AP, Klein A, Klingemann H. Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(8):1361-1368
18. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000; 95(12):3900-3908
19. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16): 3823-3837
20. Cvetković RS, Perry CM. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. BioDrugs. 2006;20(4): 253-257
21. Boland A, Bagust A, Hockenhull J, Davis H, Chu P, Dickson R. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Health Technol Assess. 2009; 13 Suppl 2:41-48
22. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001;24(3):263-271
23. Dimopoulos MA, Kastritis E, Roussou M, et al. Rituximab-based treatments in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):59-61
24. Sonet A, Bosly A. Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Rev Anticancer Ther. 2009;9(6):719-726
25. Christian BA, Lin TS. Antibody therapy for chronic lymphocytic leukemia. Semin Hematol. 2008;45(2):95-103
26. Aue G, Lindorfer MA, Beum PV, et al. Fractionated subcutaneous Rituximab is well tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica. 2010;95(9):329-332
27. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol. 2006; 177(10):7435-7443
28. Griffin TC, Weitzman S, Weinstein H, et al. Children's Oncology Group. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non- Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52(2):177-181
29. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000;27(6 Suppl 12):99-103
30. Aggarwal A, Catlett JP. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. South Med J. 2002;95(10):1209-1212
31. Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009;266(5):484-491
32. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57(2):310-317
33. Ding C, Foote S, Jones G.B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs. 2008;22(4):239-249
34. Weide R, Heymanns J, Pandorf A, Köppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus. 2003;12(10):779-782
35. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44(12):1542-1545
36. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004;22:431-456
37. Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther. 2008; 10(3):294-309
38. Roccatello D, Baldovino S, Alpa M, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S67-S71
39. Berentsen S, Tjønnfjord GE, Brudevold R, et al. Favorable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol. 2001;115(1): 79-83
40. Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia. 2007;13(1):46-50
41. Collins M, Navaneethan SD, Chung M, et al. Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis. 2008;52(6):1158-1162
42. Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008; 128(12):2745-2747
43. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9): 3107-3111
44. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56(8):2715-2718
45. Mielke F, Schneider-Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis. 2008;67(7):1056-1057
46. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs. 2007;16(5):625-633
47. Billing H, Rieger S, Ovens J, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation. 2008;86(9):1214-1221
48. Kessler L, Parissiadis A, Bayle F, et al. On behalf of the GRAGIL Study Group. Evidence for Humoral Rejection of a Pancreatic Islet Graft and Rescue with Rituximab and IV Immunoglobulin Therapy. Am J Transplant. 2009;9(8):1961-1966
49. Teshima T, Nagafuji K, Henzan H, et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol. 2009;90(2):253-260
50. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008;181(1):822-832
51. van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115(4):807-811
52. Klepfish A, Gilles L, Ioannis K, Eliezer R, Ami S. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions and clinical results in refractory CLL. Ann N Y Acad Sci. 2009;1173:865-873
53. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172(5):3280-3288
54. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101(3): 949-954
55. Racila E, Link BK, Weng WK, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res. 2008;14(20): 6697-6703
56. Cohen AM, Shinitzky M. Modulation of complement lysis of human erythrocytes by the membrane lipid viscosity. Vox Sang. 1982;43(1): 23-27
57. Semac I, Palomba C, Kulangara K, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 2003;63(2):534-540
58. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100(5):1059-1070
59. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758
60. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol. 2005;139(3):439-446
61. Petrie RJ, Deans JP. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol. 2002;169(2):2886-2891
62. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 2002;99(4):1314-1319
63. Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17): 5480-5489
64. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126
65. Mankaï A, Bordron A, Renaudineau Y, et al. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. Cancer Res. 2008;68(18):7512-7519
66. Mankaï A, Buhé V, Youinou P, Ghedira I, Berthou C, Bordron A. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated up-regulation of CD20 expression independently of PU.1. Ann N Y Acad Sci. 2009;1173:721-728
67. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005; 174(2):817-826
68. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol. 2007;179(5):3351-3361
69. Kim SJ, Lee SJ, Choi IY, et al. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol. 2008;81(3): 177-184
70. Pers JO, Devauchelle V, Daridon C, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 2007;56(5):1464-1477
71. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid enriched membrane subdomains during transport to the apical cell surface. Cell. 1992;68(3):533-544
72. Pike LJ, Han X, Chung KN, Gross RW. Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry. 2002;41(6):2075-2088
73. Fridriksson EK, Shipkova PA, Sheets ED, Holowka D, Baird B, McLafferty FW. Quantitative analysis of phospholipids in functionally important membrane domains from RBL-2H3 mast cells using tandem high-resolution mass spectrometry. Biochemistry. 1999; 38(25):8056-8063
74. Pike LJ. Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res. 2006;47(7):1597-1598
75. Rajendran L, Simons K. Lipid rafts and membrane dynamics. J Cell Sci. 2005;118(Pt6):1099-1102
76. Hanzal-Bayer MF, Hancock JF. Lipid rafts and membrane traffic. FEBS Lett. 2007;581(11):209-104
77. Sohn HW, Tolar P, Pierce SK. Membrane heterogeneities in the formation of B cell receptor-Lyn kinase microclusters and the immune synapse. J Cell Biol. 2008;182(2):367-379
78. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science. 2010;327(5961):46-50
79. Li H, Ayer LM, Polyak MJ, et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem. 2004;279(19):19893-19901
80. Setterblad N, Bécart S, Charron D, Mooney N. B cell lipid rafts regulate both peptide-dependent and peptide-independent APC-T cell interaction. J Immunol. 2004;173(3):1876-1886
81. Xia M, Wang Q, Zhu H, et al. Lipid rafts regulate cellular CD40 receptor localization in vascular endothelial cells. Biochem Biophys Res Commun. 2007;361(3):768-774
82. Oneyama C, Hikita T, Enya K, et al. The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell. 2008; 30(4):426-436
83. Spiegel S. Insertion of ganglioside GM1 into rat glioma C6 cells renders them susceptible to growth inhibition by the B subunit of cholera toxin. Biochim Biophys Acta. 1988;969(3):249-256
84. Fantini J, Maresca M, Hammache D, Yahi N, Delézay O. Glycosphingolipid (GSL) microdomains as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: activation of signal transduction pathways and perturbations of intestinal absorption and secretion. Glycoconj J. 2000;17(3-4):173-179
85. Hannun YA, Bell RM. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science. 1989; 243(4890):500-507
86. Olivera A, Buckley NE, Spiegel S. Sphingomyelinase and cell- permeable ceramide analogs stimulate cellular proliferation in quiescent Swiss 3T3 fibroblasts. J Biol Chem. 1992;267(36):26121-26127
87. Boyd RS, Jukes-Jones R, Walewska R, Brown D, Dyer MJ, Cain K. Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics. 2009;8(7): 1501-1515
88. Meyer zum Büschenfelde C, Feuerstacke Y, Götze KS, Scholze K, Peschel C. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment. Cancer Res. 2008;68(13):5414-5422
89. Daefler S, Krueger GR. Lack of dynamic lipid changes after binding of interleukin 2 in chronic lymphatic leukemia lymphocytes indicates defective transmembrane signaling. Anticancer Res. 1989;9(3): 743-748
90. Daefler S, Krueger GR. Expression of proliferation and differentiation antigens in response to modulation of membrane fluidity in chronic lymphocytic leukemia lymphocytes. Anticancer Res. 1989;9(2):501-506
91. Gouaze-Andersson V, Cabot MC. Glycosphingolipids and drug resistance. Biochim Biophys Acta. 2006;1758(12):2096-2103
92. Consoli U, Santonocito A, Stagno F, et al. Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol. 2002;116(4): 774-780
93. Jamroziak K, Smolewski P, Cebula B, Szmigielska-Kaplon A, Darzynkiewicz Z, Robak T. Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia. Neoplasma. 2004;51(3):181-187
94. Gerrard G, Butters TD, Ganeshaguru K, Mehta AB. Glucosylceramide synthase inhibitors sensitize CLL cells to cytotoxic agents without reversing P-gp functional activity. Eur J Pharmacol. 2009;609(1-3):34-39
95. Malisan F, Testi R. GD3 ganglioside and apoptosis. Biochim Biophys Acta. 2002;1585(2-3):179-187
96. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56(1):291-302
97. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(12):3955-3965
98. Yanagi S, Sugawara H, Kurosaki M, Sabe H, Yamamura H, Kurosaki T. CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells. J Biol Chem. 1996;271(48):30487-30492
99. Clatworthy MR, Willcocks L, Urban B, et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A. 2007;104(17):7169-7174
100. Kono H, Kyogoku C, Suzuki T, et al. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet. 2005;14(19): 2881-2892
101. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094-1100
102. Goldenberg DM, Rossi EA, Stein R, et al. Properties and structurefunction relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009;113(5):1062-1070
103. Du J, Wang H, Zhong C, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol. 2008;45: 2861-2868
104. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009;10(6):588-596
105. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are eff iciently killed by an anti- CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/ CD16. Br J Haematol. 2008;140(6):635-643
106. Li M, Yan Z, Han W, Zhang Y. Mimotope vaccination for epitopespecific induction of anti-CD20 antibodies. Cell Immunol. 2006; 239(2):136-143
107. Jain N, Wierda W, Ferrajoli A, et al. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer. 2009;115(19):4533-4539
108. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174
109. Bornstein GG, Quéva C, Tabrizi M, et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs. 2009
110. Li B, Shi S, Qian W, et al. Development of novel tetravalent anti- CD20 antibodies with potent antitumor activity. Cancer Res. 2008;68: 2400-2408
111. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68: 8384-8392.